Back

Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Lipid-lowering by PCSK9 modulation: what’s new? Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Lorenz Raber

Swiss Cardiovascular Center, Bern (Switzerland)

4 More presentations in this session

Presentation thumbnail
PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease
Doctor D. Kannenkeril (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data
Professor M. Svensson (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering by PCSK9 modulation: what’s new?

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
thumbnail
Congress Presentation
Effect of alirocumab on quantitative flow ratio and diameter stenosis in non-infarct related arteries from patients with acute myocardial infarction: a PACMAN-AMI randomized clinical trial substudy
thumbnail
Congress Presentation
Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources